Ikena Oncology and Vall d'Hebron Institute of Oncology Announce Research & Development CollaborationGlobeNewsWire • 05/02/22
Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual MeetingGlobeNewsWire • 04/28/22
Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate DevelopmentGlobeNewsWire • 04/13/22
Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate UpdateGlobeNewsWire • 03/17/22
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/07/22
Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific OfficerGlobeNewsWire • 12/08/21
Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175GlobeNewsWire • 11/12/21
Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate UpdateGlobeNewsWire • 11/10/21
Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930GlobeNewsWire • 11/02/21
Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer TreatmentGlobeNewsWire • 10/07/21
Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingGlobeNewsWire • 10/01/21
Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021GlobeNewsWire • 07/08/21
Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare ConferenceBusiness Wire • 05/26/21
Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021Business Wire • 05/13/21
Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional SharesBusiness Wire • 03/30/21